NLS BioInvent

BioInvent International extends manufacturing services contract with major global pharmaceutical client, expected to generate approximately SEK 8 million in revenue. BioInvent has signed an extended contract for manufacturing services with one of its current customers, a major global pharmaceutical client. The extension covers services for one of the products in the pharmaceutical company’s development portfolio. […]

BioInvent International has initiated a Phase I/IIa study that will evaluate the safety and tolerability, and explore the preliminary efficacy, of TB-403 for the treatment of relapsed or refractory medulloblastoma, a rare, life-threatening brain tumor that mainly affects children. The study initiation follows the earlier announced partnership between BioInvent, its TB-403 project partner Oncurious, and […]

BioInvent International has announced that patient recruitment into the trial can now start in the upcoming clinical Phase II study with the antibody BI-505 in patients with multiple myeloma, as necessary regulatory approvals have been obtained. Multiple myeloma is a bone marrow cancer which affects more than 120,000 people globally every year. Initial treatment is often […]

Oncurious NV, an oncology company focused on the development of orphan drugs for the treatment of pediatric tumors, has signed a partnership with the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), a collaboration of 25 US academic medical centers, teaching hospitals and other entities, with the purpose of facilitating and conducting collaborative research activities and […]

BioInvent International announces that the FDA has completed the safety review of its Investigational New Drug (IND) application and have concluded that the proposed pediatric clinical investigation can proceed. The IND application is for a Phase I/IIa study that will evaluate the efficacy and safety of TB-403 for the treatment of relapsed or refractory medulloblastoma. […]

The Swedish company BioInvent has been selected for manufacturing services by a global pharmaceutical company. BioInvent International has been selected by a major global pharmaceutical company to provide manufacturing services for one of the products in the pharmaceutical company’s development portfolio. “Being selected by this global customer to provide manufacturing services speaks to our leading […]